REFERENCES
- Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002; 54: 323–374, [PUBMED], [INFOTRIEVE], [CSA]
- Neubig R R, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003; 55: 597–606, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- May L T, Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 2003; 3: 551–556, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bruns R F, Fergus J H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharm 1990; 38: 939–949, [CSA]
- Gao Z G, Van Muijlwijk-Koezen J E, Chen A, Muller C E, Ijzerman A P, Jacobson K A. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 2001; 60: 1057–1063, [PUBMED], [INFOTRIEVE], [CSA]
- Clark A L, Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 1976; 58: 323–331, [PUBMED], [INFOTRIEVE], [CSA]
- Birdsall N J, Cohen F, Lazareno S, Matsui H. Allosteric regulation of G-protein-linked receptors. Biochem Soc Trans 1995; 23: 108–111, [PUBMED], [INFOTRIEVE], [CSA]
- Pin J P, Kniazeff J, Liu J, et al. Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 2005; 272: 2947–2955, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nemeth E F. Calcimimetic and calcilytic drugs: just for parathyroid cells?. Cell Calcium 2004; 35: 283–289, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nemeth E F. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8: 2077–2087, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jakubik J, Bacakova L, Lisa V, El-Fakahany E E, Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 1996; 93: 8705–8709, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Thomas E A, Carson M J, Neal M J, Sutcliffe J G. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA 1997; 94: 14115–14119, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kinney G G, O'Brien J A, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005; 313: 199–206, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Holst B, Elling C E, Schwartz T W. Metal-ion mediated agonism and agonist-enhancement in the melanocortin MC1 and MC4 receptors. J Biol Chem 2002; 277: 47662–47670, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Binet V, Brajon C, Le Corre L, Acher F, Pin J P, Prezeau L. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem 2004; 279: 29085–29091, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Holst B, Brandt E, Bach A, Heding A, Schwartz T W. Non-peptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 2005; 19: 2400–2411, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Urwyler S, Mosbacher J, Lingenhoehl K, et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001; 60: 963–971, [PUBMED], [INFOTRIEVE], [CSA]
- Kenakin T P. Pharmacologic Analysis of Drug-Receptor Interactions. Raven Press, New York 1993
- Monod J, Wyman J, Changeux J P. On the nature of allosteric transitions: A plausible model. J Mol Biol 1965; 12: 88–118, [PUBMED], [INFOTRIEVE], [CSA]
- Koshland D E, Jr., Nemethy G, Filmer D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 1966; 5: 365–385, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2001; 2: 274–286, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- White J H, Wise A, Main M J, et al. Heterodimerization is required for the formation of a functional GABAB receptor. Nature 1998; 396: 679–682, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kuner R, Kohr G, Grunewald S, Eisenhardt G, Bach A, Kornau H C. Role of heteromer formation in GABAB receptor function. Science 1999; 283: 74–77, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Terrillon S, Durroux T, Mouillac B, et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 2003; 17: 677–691, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004; 5: 30–34, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Baneres J L, Parello J. Structure-based analysis of GPCR function: Evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol 2003; 329: 815–829, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- El-Asmar L, Springael J Y, Ballet S, Andrieu E U, Vassart G, Parmentier M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005; 67: 460–469, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Urizar E, Montanelli L, Loy T, et al. Glycoprotein hormone receptors: Link between receptor homodimerization and negative cooperativity. EMBO J 2005; 24: 1954–1964, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mesnier D, Baneres J L. Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B(4) receptor BLT1. J Biol Chem 2004; 279: 49664–49670, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wreggett K A, Wells J W. Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 1995; 270: 22488–22499, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chidiac P, Green M A, Pawagi A B, Wells J W. Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. Biochemistry 1997; 36: 7361–7379, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sinkins W G, Kandel M, Kandel S I, Schunack W, Wells J W. G protein-linked receptors labeled by [3H]histamine in guinea pig cerebral cortex. I. Pharmacological characterization [corrected]. Mol Pharmacol 1993; 43: 569–582, [PUBMED], [INFOTRIEVE], [CSA]
- Rosenkilde M M, Lucibello M, Holst B, Schwartz T W. Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3 receptor. FEBS Lett 1998; 439: 35–40, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pin J P, Kniazeff J, Binet V, et al. Activation mechanism of the heterodimeric GABA(B) receptor. Biochem Pharmacol 2004; 68: 1565–1572, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jiang P, Cui M, Zhao B, et al. Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J Biol Chem 2005; 280: 15238–15246, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Xu H, Staszewski L, Tang H, Adler E, Zoller M, Li X. Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci USA 2004; 101: 14258–14263, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Birdsall N J, Lazareno S, Popham A, Saldanha J. Multiple allosteric sites on muscarinic receptors. Life Sci 2001; 68: 2517–2524, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lazareno S, Popham A, Birdsall N J. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol 2002; 62: 1492–1505, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Trankle C, Weyand O, Voigtlander U, et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol 2003; 64: 180–190, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Feighner S D, Howard A D, Prendergast K, et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 1998; 12: 137–145, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kniazeff J, Bessis A S, Maurel D, Ansanay H, Prezeau L, Pin J P. Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol 2004; 11: 706–713, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hofmann K P. Signalling states of photoactivated rhodopsin. Novartis Found Symp 1999; 224: 158–175, [PUBMED], [INFOTRIEVE], [CSA]
- Hlavackova V, Goudet C, Kniazeff J, et al. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J 2005; 24: 499–509, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Durroux T. Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol Sci 2005; 26: 376–384, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Murphy M G, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001; 86: 1116–1125, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bach M A, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 2004; 52: 516–523, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laferrere B, Abraham C, Russell C D, Bowers C Y. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005; 90: 611–614, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mericq V, Cassorla F, Bowers C Y, Avila A, Gonen B, Merriam G R. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab 2003; 16: 981–985, [PUBMED], [INFOTRIEVE], [CSA]
- Svensson J, Ohlsson C, Jansson J O, et al. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res 1998; 13: 1158–1166, [PUBMED], [INFOTRIEVE], [CSA]